2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Breast Neoplasms
12
Neoplasms
5
Lymphoma, Large B-Cell, Diffuse
4
Carcinoma, Non-Small-Cell Lung
4
Ovarian Neoplasms
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Carcinoma, Hepatocellular
3
Waldenstrom Macroglobulinemia
2
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Sezary Syndrome
2
Rectal Neoplasms
2
Prostatic Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Mycosis Fungoides
2
Melanoma
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, Follicular
2
Lymphoma, Extranodal NK-T-Cell
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Myeloid, Acute
2
Leukemia, Large Granular Lymphocytic
2
Leukemia, Hairy Cell
2
Intraocular Lymphoma
2
Gallbladder Neoplasms
2
Fallopian Tube Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Interventions
Doxorubicin
18
Ifosfamide
13
Radiotherapy
8
Paclitaxel
7
pazopanib
6
pembrolizumab
4
Gemcitabine
4
Filgrastim
4
Chemotherapy, Adjuvant
4
Bevacizumab
4
spartalizumab
3
durvalumab
3
Sorafenib
3
Propranolol
3
Nivolumab
3
Ipilimumab
3
Imatinib Mesylate
3
Etoposide
3
Epirubicin
3
Docetaxel
3
Carboplatin
3
trebananib
2
regorafenib
2
cixutumumab
2
cemiplimab
2
carotuximab
2
brostallicin
2
belinostat
2
balstilimab
2
Watchful Waiting
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hemangiosarcoma
×
MK 2206
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled